191 related articles for article (PubMed ID: 9679558)
1. L-S,R-buthionine sulfoximine: historical development and clinical issues.
Bailey HH
Chem Biol Interact; 1998 Apr; 111-112():239-54. PubMed ID: 9679558
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR
J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.
Bailey HH; Ripple G; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Mahvi D; Schink J; Pomplun M; Mulcahy RT; Wilding G
J Natl Cancer Inst; 1997 Dec; 89(23):1789-96. PubMed ID: 9392620
[TBL] [Abstract][Full Text] [Related]
4. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.
Villablanca JG; Volchenboum SL; Cho H; Kang MH; Cohn SL; Anderson CP; Marachelian A; Groshen S; Tsao-Wei D; Matthay KK; Maris JM; Hasenauer CE; Czarnecki S; Lai H; Goodarzian F; Shimada H; Reynolds CP
Pediatr Blood Cancer; 2016 Aug; 63(8):1349-56. PubMed ID: 27092812
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF
J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
[TBL] [Abstract][Full Text] [Related]
6. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
[TBL] [Abstract][Full Text] [Related]
7. Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
Chem Biol Interact; 1998 Apr; 111-112():277-305. PubMed ID: 9679561
[TBL] [Abstract][Full Text] [Related]
8. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
Anderson CP; Seeger RC; Satake N; Monforte-Munoz HL; Keshelava N; Bailey HH; Reynolds CP
J Pediatr Hematol Oncol; 2001 Nov; 23(8):500-5. PubMed ID: 11878777
[TBL] [Abstract][Full Text] [Related]
9. Retroviral transfer of MRP1 and gamma-glutamyl cysteine synthetase modulates cell sensitivity to L-buthionine-S,R-sulphoximine (BSO): new rationale for the use of BSO in cancer therapy.
Rappa G; Gamcsik MP; Mitina RL; Baum C; Fodstad O; Lorico A
Eur J Cancer; 2003 Jan; 39(1):120-8. PubMed ID: 12504668
[TBL] [Abstract][Full Text] [Related]
10. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
Gallo JM; Brennan J; Hamilton TC; Halbherr T; Laub PB; Ozols RF; O'Dwyer PJ
Cancer Res; 1995 Oct; 55(20):4507-11. PubMed ID: 7553617
[TBL] [Abstract][Full Text] [Related]
11. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression.
Anderson CP; Keshelava N; Satake N; Meek WH; Reynolds CP
Med Pediatr Oncol; 2000 Dec; 35(6):659-62. PubMed ID: 11107141
[TBL] [Abstract][Full Text] [Related]
12. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.
Yao K; Godwin AK; Ozols RF; Hamilton TC; O'Dwyer PJ
Cancer Res; 1993 Aug; 53(16):3662-6. PubMed ID: 8101766
[TBL] [Abstract][Full Text] [Related]
13. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
Anderson CP; Reynolds CP
Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat: enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery.
Vahrmeijer AL; van Dierendonck JH; Schutrups J; van de Velde CJ; Mulder GJ
Cancer Chemother Pharmacol; 1999; 44(2):111-6. PubMed ID: 10412944
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.
Anderson CP; Matthay KK; Perentesis JP; Neglia JP; Bailey HH; Villablanca JG; Groshen S; Hasenauer B; Maris JM; Seeger RC; Reynolds CP
Pediatr Blood Cancer; 2015 Oct; 62(10):1739-46. PubMed ID: 26153194
[TBL] [Abstract][Full Text] [Related]
16. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
Ali-Osman F; Antoun G; Wang H; Rajagopal S; Gagucas E
Mol Pharmacol; 1996 Jun; 49(6):1012-20. PubMed ID: 8649339
[TBL] [Abstract][Full Text] [Related]
17. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
18. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
19. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
Siemann DW; Beyers KL
Br J Cancer; 1993 Dec; 68(6):1071-9. PubMed ID: 8260357
[TBL] [Abstract][Full Text] [Related]
20. Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice.
Reliene R; Schiestl RH
Carcinogenesis; 2006 Feb; 27(2):240-4. PubMed ID: 16162646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
